Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.
You may also be interested in...
Study Design, Feasibility Issues Going To Pediatric Oncology Advisory Subcommittee
Four products to be considered at Nov. 1 meeting, including whether one therapy can advance a cure rate that hasn't changed in 20 years.
Study Design, Feasibility Issues Going To Pediatric Oncology Advisory Subcommittee
Four products to be considered at Nov. 1 meeting, including whether one therapy can advance a cure rate that hasn't changed in 20 years.
MedImmune's Biologic Solution To Blocking IGF In Solid Tumors Heads Into Phase II Studies
MIDI-573, which blocks insulin-like growth factor I and II while sparing receptors for normal glucose processing, heads into multiple Phase II studies this year accompanied by an assay to prospectively identify patient populations for further study, MedImmune head of oncology McMahon said in an April 4 interview at AACR.